An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
NCT ID: NCT01557348
Last Updated: 2017-01-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1239 participants
OBSERVATIONAL
2009-06-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
NCT02079532
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
NCT01196780
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
NCT01592292
An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis
NCT01071798
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
NCT01075477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rituximab
Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
No interventions assigned to this group
Alternative TNFi
Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with rheumatoid arthritis (RA) who have not responded or have been intolerant to a single TNF-inhibitor therapy
* Initiated on treatment with MabThera/Rituxan or an alternative TNF-inhibitor therapy, in accordance with the relevant Summary of Product Characteristics
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Winnipeg, Manitoba, Canada
Saint John, New Brunswick, Canada
Brampton, Ontario, Canada
Burlington, Ontario, Canada
Hamilton, Ontario, Canada
Kitchener, Ontario, Canada
London, Ontario, Canada
Mississauga, Ontario, Canada
St. Catharines, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Windsor, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Rimouski, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Barranquilla, , Colombia
Bogotá, , Colombia
Cali, , Colombia
Abbeville, , France
Aix-les-Bains, , France
Amiens, , France
Amiens, , France
Argenteuil, , France
Bayonne, , France
Belfort, , France
Besançon, , France
Bonneville, , France
Bordeaux, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Brest, , France
Bruges, , France
Bry-sur-Marne, , France
Caen, , France
Cahors, , France
Cambrai, , France
Cannes, , France
Carcassonne, , France
Carhaix-Plouguer, , France
Chambray-lès-Tours, , France
Clermont-Ferrand, , France
Clermont-Ferrand, , France
Colmar, , France
Corbeil-Essonnes, , France
Draguignan, , France
Échirolles, , France
Évreux, , France
Issy-les-Moulineaux, , France
La Roche-sur-Yon, , France
La Source, , France
Laon, , France
Laval, , France
Le Coudray, , France
Le Kremlin-Bicêtre, , France
Le Mans, , France
Libourne, , France
Liévin, , France
Lille, , France
Limoges, , France
Limoges, , France
Lomme, , France
Lorient, , France
Lyon, , France
Lyon, , France
Lyon, , France
Maisons-Laffitte, , France
Mantes-la-Jolie, , France
Marseille, , France
Marseille, , France
Mennecy, , France
Metz, , France
Montauban, , France
Montauban, , France
Montivilliers, , France
Montpellier, , France
Mulhouse, , France
Nantes, , France
Nevers, , France
Nice, , France
Pachuca, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Pierre-Bénite, , France
Reims, , France
Reims, , France
Rennes, , France
Rodez, , France
Roubaix, , France
Saint-Aubin-lès-Elbeuf, , France
Saint-Brieuc, , France
Saint-Priest-en-Jarez, , France
Toulon, , France
Toulouse, , France
Toulouse, , France
Tours, , France
Valence, , France
Valenciennes, , France
Vandœuvre-lès-Nancy, , France
Vannes, , France
Villeneuve-sur-Lot, , France
Vincennes, , France
Aachen, , Germany
Bremen, , Germany
Cologne, , Germany
Cuxhaven, , Germany
Erlangen, , Germany
Frankenberg, , Germany
Frankfurt, , Germany
Gräfelfing, , Germany
Halle, , Germany
Hanover, , Germany
Münster, , Germany
Neuss, , Germany
Rostock, , Germany
Villingen-Schwenningen, , Germany
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Larissa, , Greece
Coppito, Abruzzo, Italy
Bari, Apulia, Italy
San Cesario di Lecce, Apulia, Italy
Potenza, Basilicate, Italy
Napoli, Campania, Italy
Telese Terme, Campania, Italy
Ferrara, Emilia-Romagna, Italy
Modena, Emilia-Romagna, Italy
Udine, Friuli Venezia Giulia, Italy
Milan, Lombardy, Italy
Milan, Lombardy, Italy
Gazzi, Sicily, Italy
Palermo, Sicily, Italy
Ancona, The Marches, Italy
Iesi, The Marches, Italy
Florence, Tuscany, Italy
Pisa, Tuscany, Italy
Prato, Tuscany, Italy
Siena, Tuscany, Italy
Padua, Veneto, Italy
Verona, Veneto, Italy
Chihuahua City, , Mexico
Mexicali, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Poza Rica Chacas, , Mexico
Monaco, , Monaco
Ålesund, , Norway
Amadora, , Portugal
Guimarães, , Portugal
Lisbon, , Portugal
Porto, , Portugal
Córdoba, Cordoba, Spain
Granada, Granada, Spain
Granada, Granada, Spain
León, Leon, Spain
Lugo, Lugo, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
El Palmar, Murcia, Spain
Lorca, Murcia, Spain
Salamanca, Salamanca, Spain
Seville, Sevilla, Spain
Torrevieja, , Spain
Abergavenny, , United Kingdom
Aylesbury, , United Kingdom
Blackburn, , United Kingdom
Cambridge, , United Kingdom
Cannock, , United Kingdom
Cardiff, , United Kingdom
Cheltenham, , United Kingdom
Chertsey, , United Kingdom
Cosham, , United Kingdom
Derby, , United Kingdom
Durham, , United Kingdom
Exeter, , United Kingdom
Glasgow, , United Kingdom
Harrogate, , United Kingdom
Inverness, , United Kingdom
Lancaster, , United Kingdom
Leeds, , United Kingdom
Lincoln, , United Kingdom
Liverpool, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Metropolitan Borough of Wirral, , United Kingdom
Poole, , United Kingdom
Salford, , United Kingdom
Solihull, , United Kingdom
Southport, , United Kingdom
St Helens, , United Kingdom
Stockport, , United Kingdom
Sunderland, , United Kingdom
Sutton in Ashfield, , United Kingdom
Torquay, , United Kingdom
Truro, , United Kingdom
Warrington, , United Kingdom
Wolverhampton, , United Kingdom
Worthing, , United Kingdom
Wrightington, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA22401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.